These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37806791)

  • 1. Corrigendum to "Sophoricoside attenuates lipopolysaccharide-induced acute lung injury by activating the AMPK/Nrf2 signaling axis" [Int. Immunopharmacol. 90 (2021) 107187].
    Wu YX; Zeng S; Wan BB; Wang YY; Sun HX; Liu G; Gao ZQ; Chen D; Chen YQ; Lu MD; Pang QF
    Int Immunopharmacol; 2023 Nov; 124(Pt A):111008. PubMed ID: 37806791
    [No Abstract]   [Full Text] [Related]  

  • 2. Sophoricoside attenuates lipopolysaccharide-induced acute lung injury by activating the AMPK/Nrf2 signaling axis.
    Wu YX; Zeng S; Wan BB; Wang YY; Sun HX; Liu G; Gao ZQ; Chen D; Chen YQ; Lu MD; Pang QF
    Int Immunopharmacol; 2021 Jan; 90():107187. PubMed ID: 33249045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum to "Salidroside postconditioning attenuates ferroptosis-mediated lung ischemia-reperfusion injury by activating the Nrf2/SLC7A11 signaling axis" [Int. Immunopharmacol. 115 (2023) 109731].
    Wang Y; Chen Z; Luo J; Zhang J; Sang AM; Cheng ZS; Li XY
    Int Immunopharmacol; 2023 Apr; 117():110002. PubMed ID: 36925352
    [No Abstract]   [Full Text] [Related]  

  • 4. Corrigendum to "GTS-21 attenuates ACE/ACE2 ratio and glycocalyx shedding in lipopolysaccharide-induced acute lung injury by targeting macrophage polarization derived ADAM-17" [Int. Immunopharmacol. 129 (2024) 111603].
    Zhu W; Wang F; Hu C; Zhao Q; Zhang D; Wang X; Hu B; Li J
    Int Immunopharmacol; 2024 May; 132():111914. PubMed ID: 38582738
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrigendum to "Maackiain protects against sepsis via activating AMPK/Nrf2/HO-1 pathway" [Int. Immunopharmacol. 108 (2022) 108710].
    Bai X; Zhu Y; Jie J; Li D; Song L; Luo J
    Int Immunopharmacol; 2024 Oct; 140():112877. PubMed ID: 39127491
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrigendum to "Ghrelin attenuates secondary brain injury following intracerebral hemorrhage by inhibiting NLRP3 inflammasome activation and promoting Nrf2/ARE signaling pathway in mice" [Int. Immunopharmacol. 79 (2020) 106180].
    Cheng Y; Chen B; Xie W; Chen Z; Yang G; Cai Y; Shang H; Zhao W
    Int Immunopharmacol; 2020 Jul; 84():106461. PubMed ID: 32278662
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "Paeonol derivative-6 attenuates inflammation by activating ZEB2 in acute liver injury" [Int. Immunopharmacol. 91 (2021) 107235].
    Yang J; Xu L; Wu M; Fang H; Lu Y; Shi C; Wang Y; Li Z; Zhang L; Zhang L
    Int Immunopharmacol; 2021 May; 94():107410. PubMed ID: 33578262
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "Emodin attenuates acute lung injury in cecal-ligation and puncture rats" [Int. Immunopharmacol. 85 (2020) 106626].
    Guo R; Li Y; Han M; Liu J; Sun Y
    Int Immunopharmacol; 2023 Sep; 122():110700. PubMed ID: 37507324
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "PAD4 selective inhibitor TDFA protects lipopolysaccharide-induced acute lung injury by modulating nuclear p65 localization in epithelial cells" [Int. Immunopharmacol. 88 (2020) 106923].
    Zhao X; Gu C; Wang Y
    Int Immunopharmacol; 2023 Dec; 125(Pt B):111185. PubMed ID: 37957096
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "Taxifolin ameliorates Benzo[a]pyrene-induced lung injury possibly via stimulating the Nrf2 signalling pathway" [Int. Immunopharmacol. 96 (2021) 107566].
    Islam J; Shree A; Vafa A; Afzal SM; Sultana S
    Int Immunopharmacol; 2023 Jun; 119():110096. PubMed ID: 37095029
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Epigallocatechin gallate potentially abrogates fluoride induced lung oxidative stress, inflammation via Nrf2/Keap1 signaling pathway in rats: An in-vivo and in-silico study" [Int. Immunopharmacol. 39 (2016) 128-139].
    Shanmugam T; Selvaraj M; Poomalai S
    Int Immunopharmacol; 2020 Mar; 80():106203. PubMed ID: 31983588
    [No Abstract]   [Full Text] [Related]  

  • 12. Retraction notice to "Corrigendum to "MLL1 promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by activating the TRIF/NF-κB signaling pathway via H3K4me3 enrichment in the TLR4 promoter region"" [Int. Immunopharmacol. 82 (2020) 106220] [Int. Immunopharmacol. 92 (2021) 107321].
    Zhang Y; Ji T; Ma S; Wu W
    Int Immunopharmacol; 2023 Apr; 117():109865. PubMed ID: 36822094
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "Methylallyl sulfone attenuates inflammation, oxidative stress and lung injury induced by cigarette smoke extract in mice and RAW264.7 cells" Int Immunopharmacol, volume 59, 2018, 369-374.
    Li A; Liu Y; Zhu X; Sun X; Feng X; Li D; Zhang J; Zhu M; Zhao Z
    Int Immunopharmacol; 2019 Jul; 72():522. PubMed ID: 30922802
    [No Abstract]   [Full Text] [Related]  

  • 14. Ethyl ferulate protects against lipopolysaccharide-induced acute lung injury by activating AMPK/Nrf2 signaling pathway.
    Wu YX; Wang YY; Gao ZQ; Chen D; Liu G; Wan BB; Jiang FJ; Wei MX; Zuo J; Zhu J; Chen YQ; Qian F; Pang QF
    Acta Pharmacol Sin; 2021 Dec; 42(12):2069-2081. PubMed ID: 34417573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xanthohumol ameliorates lipopolysaccharide (LPS)-induced acute lung injury via induction of AMPK/GSK3β-Nrf2 signal axis.
    Lv H; Liu Q; Wen Z; Feng H; Deng X; Ci X
    Redox Biol; 2017 Aug; 12():311-324. PubMed ID: 28285192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum to "Icariin targets Nrf2 signaling to inhibit microglia-mediated neuroinflammation" [Int. Immunopharmacol. 73 (2019) 304-311].
    Zheng Y; Zhu G; He J; Wang G; Li D; Zhang F
    Int Immunopharmacol; 2020 Nov; 88():107004. PubMed ID: 32950402
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Gypenoside XLIX attenuates sepsis-induced splenic injury through inhibiting inflammation and oxidative stress" [Int. Immunopharmacol. 127 (2024) 111420].
    Xu B; Yang R; Qiang J; Xu X; Zhou M; Ji X; Lu Y; Dong Z
    Int Immunopharmacol; 2024 Apr; 131():111694. PubMed ID: 38368241
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "7-Deacetyl-gedunin suppresses proliferation of Human rheumatoid arthritis synovial fibroblast through activation of Nrf2/ARE signaling" [Int. Immunopharmacol. 107 (2022) 108557].
    Chen J; Zhu G; Sun Y; Wu Y; Wu B; Zheng W; Ma X; Zheng Y
    Int Immunopharmacol; 2023 Sep; 122():110702. PubMed ID: 37544812
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Dioscin reduces lipopolysaccharide-induced inflammatory liver injury via regulating TLR4/MyD88 signal pathway" [Int. Immunopharmacol. 36 (2016) 132-141].
    Yao H; Hu C; Yin L; Tao X; Xu L; Qi Y; Han X; Xu Y; Zhao Y; Wang C; Peng J
    Int Immunopharmacol; 2019 Sep; 74():105786. PubMed ID: 31402320
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "Inhibition of MRP4 alleviates sepsis-induced acute lung injury in rats" [Int. Immunopharmacol. 72 (2019) 211-217].
    Xia W; Zhang H; Pan Z; Li G; Zhou Q; Hu D; Liu Y
    Int Immunopharmacol; 2023 Sep; 122():110699. PubMed ID: 37500384
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.